The almost Holy Grail in psychiatry would be, based on a patient’s symptoms, to say ‘You should get TMS, and we should target this part of the brain for best results.’” The Brainsway transcranial magnetic stimulation machine.
“We now know there are different kinds of depression. “In treating depression with TMS, it’s been standard to target one specific region, but this still leaves some patients who don’t improve,” he said. George is looking to better those numbers by personalizing TMS. By the end of the six-week cycle, depression is resolved in about one-third of patients and is decreased in another third. But for the remaining 20%, finding an effective drug treatment becomes vanishingly slim.”īy the second week of TMS treatment, most of these patients who have not responded to medications are experiencing fewer depressive symptoms. “About 60% respond well to therapy and medication, and another 20% respond when switched to an alternative medication. “In the U.S., at any moment,1 in 20 people is depressed in some capacity,” said George.
TMS can offer a lifeline for those whose depression does not respond to antidepressants. The almost Holy Grail in psychiatry would be, based on a patient’s symptoms, to say ‘You should get TMS, and we should target this part of the brain for best results.’” - Dr. George is a pioneer in the field, whose work helped TMS to gain approval in 2008 from the U.S. TMS uses a magnet to increase brain activity in a region of the brain known as the dorsolateral prefrontal cortex to treat clinical depression. That’s certainly needed when it comes to using transcranial magnetic stimulation (TMS) to treat depression, said MUSC Distinguished University Professor Mark George, M.D. However, what continues to be needed in virtually every field is a personalized approach to care.
It’s safe to say the past few decades have felt like the next big wave of medicine.
0 kommentar(er)
